Blackstone to Make Equity Investment in Cryoport in Connection With Acquisition of MVE Biological Solutions From Chart Industries



Anthony F. Vernace Anthony F. Vernace
Matthew Gabbard Matthew Gabbard
Jonathan Ozner Jonathan Ozner
Daniel N. Webb Daniel N. Webb
Jonathan Goldstein Jonathan Goldstein
+11

Simpson Thacher is representing Blackstone in a combination preferred and common equity investment in Cryoport, Inc. (“Cryoport”) in connection with Cryoport’s announced acquisition of MVE Biological Solutions (“MVE”) from Chart Industries, Inc. for approximately $320 million. Investment vehicles affiliated with Blackstone Tactical Opportunities agreed to purchase $250 million of Cryoport’s Series C Convertible Preferred Stock and $25 million of Cryoport’s Common Stock. The transactions are subject to customary closing conditions, including obtaining regulatory approvals, and are expected to close by the end of 2020.

Cryoport is a global leader in temperature-controlled supply chain solutions for the life sciences industry. MVE is a global leader in manufactured vacuum-insulated products and cryogenic freezer systems for the life sciences industry.

The Simpson Thacher team includes Anthony Vernace, Matthew Gabbard, Donovan Westbrook and Hadley Nagel (M&A); Jonathan Ozner (Capital Markets); Dan Webb (Palo Alto Capital Markets); Jonathan Goldstein and Eli Shalam (Tax); Peter Gilman, Matthew Leighton, Caitlin Lackner and Hongda Wang (Funds); Jonathan Lindabury, Jennifer Levitt and Caitlin Wood (Credit/Derivatives); Jeanne Annarumma (ERISA); Greg Grogan and Pasco Struhs (Executive Compensation & Employee Benefits); Peter Guryan, Kelly Karapetyan and Daniel Owsley (Antitrust); Lori Lesser and Bobbie Burrows (Intellectual Property); and Adeeb Fadil and Timothy Mulvihill (Environmental).